Eli Lilly Valuation

LLY Stock  EUR 767.80  2.90  0.38%   
At this time, the firm appears to be overvalued. Eli Lilly shows a prevailing Real Value of €728.25 per share. The current price of the firm is €767.8. Our model computes the value of Eli Lilly from reviewing the firm fundamentals such as EBITDA of 8.28 B, price to sales of 11.53 X, and Net Income of 6.24 B as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
767.80
Please note that Eli Lilly's price fluctuation is very steady at this time. Calculation of the real value of Eli Lilly is based on 3 months time horizon. Increasing Eli Lilly's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Eli stock is determined by what a typical buyer is willing to pay for full or partial control of Eli Lilly and. Since Eli Lilly is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eli Stock. However, Eli Lilly's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  767.8 Real  728.25 Hype  767.8
The intrinsic value of Eli Lilly's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Eli Lilly's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
725.79
Downside
728.25
Real Value
844.58
Upside
Estimating the potential upside or downside of Eli Lilly and helps investors to forecast how Eli stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eli Lilly more accurately as focusing exclusively on Eli Lilly's fundamentals will not take into account other important factors:
Hype
Prediction
LowEstimatedHigh
765.34767.80770.26
Details

Eli Lilly Total Value Analysis

Eli Lilly and is now anticipated to have takeover price of 337.36 B with market capitalization of 337.36 B, debt of 15.35 B, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Eli Lilly fundamentals before making investing decisions based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
337.36 B
337.36 B
15.35 B

Eli Lilly Asset Utilization

The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The recent return on assets of Eli suggests not a very effective usage of assets in December.

Eli Lilly Profitability Analysis

The company reported the revenue of 28.54 B. Net Income was 6.24 B with profit before overhead, payroll, taxes, and interest of 0.

About Eli Lilly Valuation

We use absolute and relative valuation methodologies to arrive at the intrinsic value of Eli Lilly and. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Eli Lilly based exclusively on its fundamental and basic technical indicators. By analyzing Eli Lilly's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Eli Lilly's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Eli Lilly. We calculate exposure to Eli Lilly's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Eli Lilly's related companies.

8 Steps to conduct Eli Lilly's Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Eli Lilly's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Eli Lilly's valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Eli Lilly's financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Eli Lilly's revenue streams: Identify Eli Lilly's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Eli Lilly's industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Eli Lilly's growth potential: Evaluate Eli Lilly's management, business model, and growth potential.
  • Determine Eli Lilly's financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Eli Lilly's estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Additional Information and Resources on Investing in Eli Stock

When determining whether Eli Lilly offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.